Index S&P 500
P/E 109.60
EPS (ttm) 2.10
Insider Own 0.10%
Shs Outstand 1.77B
Perf Week 0.05%
Market Cap 406.84B
Forward P/E 16.11
EPS next Y 14.30
Insider Trans -3.05%
Shs Float 1.76B
Perf Month 5.48%
Enterprise Value 470.90B
PEG 6.77
EPS next Q 2.56
Inst Own 74.23%
Short Float 0.92%
Perf Quarter 23.56%
Income 3.72B
P/S 6.98
EPS this Y 13.62%
Inst Trans -0.11%
Short Ratio 3.02
Perf Half Y 31.56%
Sales 58.33B
P/B -
EPS next Y 24.36%
ROA 2.67%
Short Interest 16.29M
Perf YTD 29.60%
Book/sh -0.10
P/C 62.91
EPS next 5Y 16.20%
ROE 112.90%
52W High 244.81 -5.93%
Perf Year 18.25%
Cash/sh 3.66
P/FCF 22.31
EPS past 3/5Y -28.18% -14.67%
ROIC 5.93%
52W Low 163.81 40.59%
Perf 3Y 64.16%
Dividend Est. 6.53 (2.84%)
EV/EBITDA 17.60
Sales past 3/5Y 0.08% 11.11%
Gross Margin 70.97%
Volatility 1.90% 2.12%
Perf 5Y 168.13%
Dividend TTM 6.47 (2.81%)
EV/Sales 8.07
EPS Y/Y TTM -29.75%
Oper. Margin 31.61%
ATR (14) 4.90
Perf 10Y 306.32%
Dividend Ex-Date Oct 15, 2025
Quick Ratio 0.61
Sales Y/Y TTM 6.05%
Profit Margin 6.38%
RSI (14) 58.98
Recom 1.90
Dividend Gr. 3/5Y 5.81% 7.46%
Current Ratio 0.74
EPS Q/Q -31.76%
SMA20 1.43%
Beta 0.50
Target Price 235.28
Payout 263.15%
Debt/Eq -
Sales Q/Q 6.65%
SMA50 7.00%
Rel Volume 0.86
Prev Close 230.50
Employees 55000
LT Debt/Eq -
Earnings Oct 31 BMO
SMA200 17.47%
Avg Volume 5.40M
Price 230.30
IPO Dec 10, 2012
Option/Short Yes / Yes
EPS/Sales Surpr. 3.12% 2.62%
Trades
Volume 4,631,474
Change -0.09%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-01-25 Downgrade
HSBC Securities
Buy → Hold
Sep-17-25 Upgrade
Berenberg
Hold → Buy
$270
Aug-12-25 Resumed
Piper Sandler
Overweight
$231
Aug-07-25 Upgrade
Daiwa Securities
Neutral → Outperform
$214
May-14-25 Downgrade
Citigroup
Buy → Neutral
$205
Apr-22-25 Initiated
Cantor Fitzgerald
Overweight
$210
Dec-10-24 Resumed
BofA Securities
Neutral
$191
Dec-05-24 Downgrade
Daiwa Securities
Outperform → Neutral
$180
Nov-22-24 Upgrade
Leerink Partners
Market Perform → Outperform
$206
Nov-15-24 Initiated
Wolfe Research
Outperform
$205
Nov-04-24 Upgrade
Argus
Hold → Buy
Oct-17-24 Initiated
Bernstein
Mkt Perform
$203
Jun-05-24 Upgrade
HSBC Securities
Hold → Buy
$185
May-17-24 Initiated
Cantor Fitzgerald
Overweight
$200
Jan-29-24 Upgrade
William Blair
Mkt Perform → Outperform
Dec-18-23 Downgrade
HSBC Securities
Buy → Hold
Dec-11-23 Upgrade
Goldman
Neutral → Buy
Nov-09-23 Initiated
Deutsche Bank
Hold
$150
Oct-30-23 Upgrade
Barclays
Equal Weight → Overweight
$160 → $170
Oct-20-23 Resumed
UBS
Neutral
$157 → $150
Show Previous Ratings
Today 01:49PM
01:40PM
10:57AM
09:53AM
07:15AM
09:00AM
Loading…
Oct-10-25 09:00AM
02:59AM
Oct-09-25 10:14AM
08:00AM
02:05AM
Oct-08-25 10:22AM
10:03AM
07:16AM
03:41AM
Oct-07-25 04:44AM
05:25PM
Loading…
Oct-06-25 05:25PM
01:57PM
10:11AM
09:03AM
09:00AM
08:32AM
Oct-03-25 04:55PM
04:21PM
(Investor's Business Daily)
09:59AM
06:27AM
12:38AM
Oct-02-25 05:45PM
09:23AM
08:00AM
02:55AM
02:08AM
Loading…
02:08AM
Oct-01-25 06:36PM
04:01PM
01:57PM
11:37AM
(Pharmaceutical Technology)
10:15AM
09:22AM
08:00AM
05:31AM
05:25AM
Sep-30-25 04:05PM
03:00PM
11:47AM
(The Wall Street Journal)
04:00AM
Sep-29-25 02:36PM
12:00PM
09:11AM
09:00AM
09:00AM
04:42AM
Sep-28-25 10:00AM
Sep-26-25 04:51PM
11:45AM
09:58AM
08:45AM
08:15AM
Sep-25-25 05:00AM
05:00AM
04:44AM
Sep-24-25 05:45PM
Sep-23-25 02:47PM
05:00AM
Sep-22-25 09:20PM
05:31PM
11:13AM
04:46AM
Sep-21-25 09:19AM
Sep-20-25 11:18PM
05:30AM
(The Wall Street Journal)
Sep-19-25 12:03PM
08:59AM
08:59AM
04:44AM
Sep-18-25 04:15PM
11:30AM
11:04AM
Sep-17-25 05:45PM
04:11PM
(Investor's Business Daily)
02:17PM
12:54PM
09:33AM
Sep-16-25 02:58PM
10:51AM
09:54AM
Sep-13-25 06:42AM
Sep-12-25 08:14PM
01:48PM
01:30PM
12:11PM
09:57AM
09:21AM
09:18AM
08:55AM
07:25AM
(Pharmaceutical Technology)
04:46AM
Sep-11-25 06:48PM
03:43PM
02:10PM
(The Wall Street Journal)
01:30PM
12:45PM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Richard A. Gonzalez Former Director Aug 22 '25 Proposed Sale 210.84 62,755 13,231,264 Aug 22 06:02 PM Richard A. Gonzalez Former Director Aug 21 '25 Proposed Sale 211.04 90,000 18,993,948 Aug 21 06:04 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Aug 12 '25 Option Exercise 54.86 42,370 2,324,418 219,662 Aug 14 05:00 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Aug 12 '25 Sale 198.42 42,370 8,407,055 177,292 Aug 14 05:00 PM AZITA SALEKI-GERHARDT Officer Aug 12 '25 Proposed Sale 198.42 42,370 8,407,068 Aug 12 07:22 PM Richard A. Gonzalez Former Director Aug 01 '25 Proposed Sale 195.83 61,500 12,043,268 Aug 08 05:03 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Aug 05 '25 Sale 198.51 13,295 2,639,253 58,247 Aug 07 05:00 PM NICHOLAS DONOGHOE Officer Aug 05 '25 Proposed Sale 198.51 13,299 2,639,966 Aug 05 04:40 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 31 '25 Option Exercise 79.02 25,700 2,030,814 112,066 Apr 02 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 31 '25 Sale 210.08 58,832 12,359,504 53,234 Apr 02 05:00 PM Stewart Jeffrey Ryan Officer Mar 31 '25 Proposed Sale 210.09 58,832 12,359,897 Mar 31 05:30 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Mar 14 '25 Sale 212.34 17,644 3,746,527 11,577 Mar 18 05:00 PM Reents Scott T Officer Mar 14 '25 Proposed Sale 212.35 17,644 3,746,628 Mar 14 04:34 PM GONZALEZ RICHARD A Director Feb 28 '25 Sale 205.11 92,460 18,964,471 395,097 Mar 04 05:00 PM GONZALEZ RICHARD A Director Mar 03 '25 Sale 210.53 6,168 1,298,549 388,929 Mar 04 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Mar 03 '25 Option Exercise 159.88 18,008 2,879,040 22,627 Mar 04 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Mar 03 '25 Sale 210.00 18,008 3,781,680 4,619 Mar 04 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Feb 28 '25 Sale 206.30 9,892 2,040,722 4,619 Mar 04 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 03 '25 Sale 210.45 21,250 4,472,039 6,130 Mar 04 05:00 PM GONZALEZ RICHARD A Officer Mar 03 '25 Proposed Sale 210.53 6,168 1,298,550 Mar 03 05:57 PM PERRY C SIATIS Officer Mar 03 '25 Proposed Sale 210.00 18,008 3,781,680 Mar 03 04:28 PM TIMOTHY RICHMOND Officer Mar 03 '25 Proposed Sale 210.46 21,250 4,472,184 Mar 03 04:08 PM GONZALEZ RICHARD A Officer Feb 28 '25 Proposed Sale 205.11 92,460 18,964,882 Feb 28 05:37 PM Buckbee Kevin K SVP, CONTROLLER Feb 26 '25 Option Exercise 98.48 16,260 1,601,313 28,906 Feb 28 05:00 PM Buckbee Kevin K SVP, CONTROLLER Feb 26 '25 Sale 203.41 18,944 3,853,372 11,496 Feb 28 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Feb 26 '25 Option Exercise 114.36 22,210 2,539,936 66,494 Feb 28 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Feb 26 '25 Sale 202.90 29,917 6,070,036 44,284 Feb 28 05:00 PM PERRY C SIATIS Officer Feb 28 '25 Proposed Sale 206.31 9,892 2,040,790 Feb 28 04:12 PM Buckbee Kevin K Officer Feb 26 '25 Proposed Sale 203.41 18,944 3,853,398 Feb 26 05:47 PM TIMOTHY RICHMOND Officer Feb 26 '25 Proposed Sale 202.90 29,917 6,070,176 Feb 26 04:04 PM Siatis Perry C EVP, GC AND SECRETARY Feb 20 '25 Sale 197.90 5,778 1,143,453 22,381 Feb 24 05:00 PM PERRY C SIATIS Officer Feb 20 '25 Proposed Sale 197.90 5,778 1,143,492 Feb 20 04:10 PM Buckbee Kevin K SVP, CONTROLLER Dec 16 '24 Option Exercise 93.50 1,800 168,300 8,783 Dec 18 05:00 PM Buckbee Kevin K SVP, CONTROLLER Dec 16 '24 Sale 172.24 1,800 310,032 6,983 Dec 18 05:00 PM Buckbee Kevin K Officer Dec 16 '24 Proposed Sale 172.25 1,800 310,045 Dec 16 05:34 PM